The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Treating infections caused by carbapenemase-producing Enterobacteriaceae
Open accessAbstract
Carbapenemase-producing Enterobacteriaceae (CPE) have spread worldwide, causing serious infections with increasing frequency. CPE are resistant to almost all available antibiotics, complicating therapy and limiting treatment options. Mortality rates associated with CPE infections are unacceptably high, indicating that the current therapeutic approaches are inadequate and must be revised. Here, we review 20 clinical studies (including those describing the largest cohorts of CPE-infected patients) that provided the necessary information regarding isolate and patient characteristics and treatment schemes, as well as a clear assessment of outcome. The data summarized here indicate that treatment with a single in vitro active agent resulted in mortality rates not significantly different from that observed in patients treated with no active therapy, whereas combination therapy with two or more in vitro active agents was superior to monotherapy, providing a clear survival benefit (mortality rate, 27.4% vs. 38.7%; p <0.001). The lowest mortality rate (18.8%) was observed in patients treated with carbapenem-containing combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumarasamy, K. K., Toleman, M. A., Walsh, T. R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C. G., Irfan, S., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70143-2 · Cited by 2,922
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
Self-citationGram-Negative Bacteremia: I. Etiology and Ecology
McCABE, W. R. (1962) · Archives of Internal Medicine · doi:10.1001/archinte.1962.03620240029006 · Cited by 1,362
Kreger, B. E., Craven, D. E., & McCabe, W. R. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90102-3 · Cited by 1,314
Tzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T., & Daikos, G. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05035-11 · Cited by 1,191
Self-citationTumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
Emergence of Oxacillinase-Mediated Resistance to Imipenem in Klebsiella pneumoniae
Poirel, L., Héritier, C., Tolün, V., & Nordmann, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.15-22.2004 · Cited by 997
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe
Cantón, R., Akóva, M., Carmeli, Y., Giske, C. G., Glupczynski, Y., Gniadkowski, M., Livermore, D. M., Miriagou, V., Naas, T., Rossolini, G. M., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03821.x · Cited by 883
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
Agwuh, K. N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl224 · Cited by 806
Garonzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
The emerging NDM carbapenemases
Nordmann, P., Poirel, L., Walsh, T. R., & Livermore, D. M. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.09.005 · Cited by 663
Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02166-13 · Cited by 597
Self-citationQureshi, Z. A., Paterson, D. L., Potoski, B. A., Kilayko, M. C., Sandovsky, G., Sordillo, E., Polsky, B., Adams-Haduch, J. M., & Doi, Y. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06268-11 · Cited by 559
Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., Karaiskos, I., Poulakou, G., Kontopidou, F., Armaganidis, A., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01361-08 · Cited by 494
Hirsch, E. B., & Tam, V. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq108 · Cited by 477
Zarkotou, O., Pournaras, S., Tselioti, P., Dragoumanos, V., Pitiriga, V., Ranellou, K., Prekates, A., Themeli-Digalaki, K., & Tsakris, A. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03514.x · Cited by 438
New antibiotics for bad bugs: where are we?
Bassetti, M., Merelli, M., Temperoni, C., & Astilean, A. (2013) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-12-22 · Cited by 403
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes
van Duin, D., Kaye, K. S., Neuner, E. A., & Bonomo, R. A. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.11.009 · Cited by 352
Capone, A., Giannella, M., Fortini, D., Giordano, A., Meledandri, M., Ballardini, M., Venditti, M., Bordi, E., Capozzi, D., Balice, M. P., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12070 · Cited by 346
Fernández, L., Gooderham, W. J., Bains, M., McPhee, J. B., Wiegand, I., & Hancock, R. E. W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00242-10 · Cited by 320
Nordmann, P., Poirel, L., Toleman, M. A., & Walsh, T. R. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq520 · Cited by 294
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00826-13 · Cited by 286
Souli, M., Galani, I., Antoniadou, A., Papadomichelakis, E., Poulakou, G., Panagea, T., Vourli, S., Zerva, L., Armaganidis, A., Kanellakopoulou, K., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649865 · Cited by 271
Self-citationActivity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
Livermore, D. M., Warner, M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt178 · Cited by 268
Wachino, J., & Arakawa, Y. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.05.001 · Cited by 255
Satlin, M. J., Jenkins, S. G., & Walsh, T. J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu052 · Cited by 255
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Zusman, O., Avni, T., Leibovici, L., Adler, A., Friberg, L., Stergiopoulou, T., Carmeli, Y., & Paul, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01230-13 · Cited by 233
Pontikis, K., Karaiskos, I., Bastani, S., Dimopoulos, G., Kalogirou, M., Katsiari, M., Oikonomou, A., Poulakou, G., Roilides, E., & Giamarellou, H. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.09.010 · Cited by 220
Daikos, G. L., Petrikkos, P., Psichogiou, M., Kosmidis, C., Vryonis, E., Skoutelis, A., Georgousi, K., Tzouvelekis, L. S., Tassios, P. T., Bamia, C., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00782-08 · Cited by 210
Self-citationColistin resistance in Klebsiella pneumoniae
Ah, Y.-M., Kim, A.-J., & Lee, J.-Y. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.02.016 · Cited by 200
Dudhani, R. V., Turnidge, J. D., Nation, R. L., & Li, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq226 · Cited by 181
Stachyra, T., Levasseur, P., Pechereau, M.-C., Girard, A.-M., Claudon, M., Miossec, C., & Black, M. T. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp197 · Cited by 180
Treatment of carbapenem-resistantKlebsiella pneumoniae: the state of the art
Petrosillo, N., Giannella, M., Lewis, R. E., & Viale, P. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.162 · Cited by 178
Escherichia coli producing VIM-1 carbapenemase isolated on a pig farm
Fischer, J., Rodríguez, I., Schmoger, S., Friese, A., Roesler, U. H., Helmuth, R., & Guerra, B. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks108 · Cited by 175
Mouloudi, E. K., Protonotariou, E., Zagorianou, A., Iosifidis, Ε., Karapanagiotou, A., Giasnetsova, T., Tsioka, A., Roilides, E., Sofianou, D., & Gritsi-Gerogianni, N. (2010) · Infection Control and Hospital Epidemiology · doi:10.1086/657135 · Cited by 171
A review of tigecycline — the first glycylcycline
Peterson, L. R. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(09)70005-6 · Cited by 161
Salmonella enterica subsp. enterica producing VIM-1 carbapenemase isolated from livestock farms
Fischer, J., Rodríguez, I., Schmoger, S., Friese, A., Roesler, U. H., Helmuth, R., & Guerra, B. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks393 · Cited by 156
Bergamasco, M. D., Barbosa, M. B., Garcia, D. D. O., Cipullo, R., Moreira, J. C. M., Baía, C. E. S., Barbosa, V. S. A., & Abboud, C. S. (2011) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2011.00688.x · Cited by 153
Status report on carbapenemases: challenges and prospects
Patel, G., & Bonomo, R. A. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.28 · Cited by 146
Combination therapy for carbapenem-resistant Gram-negative bacteria
Zavascki, A. P., Bulitta, J. B., & Landersdorfer, C. B. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.845523 · Cited by 144
Villa, L., Feudi, C., Fortini, D., García-Fernández, A., & Carattoli, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01803-13 · Cited by 138
Mammina, C., Bonura, C., Bernardo, F. D., et al. (2012) · Eurosurveillance · doi:10.2807/ese.17.33.20248-en · Cited by 137
Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece)
Maltezou, H. C., Giakkoupi, P., Maragos, A., Bolikas, E., Raftopoulos, V., Papahatzaki, H., Vrouhos, G., Liakou, V., & Vatopoulos, A. C. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.01.010 · Cited by 135
Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge
Francisco, C. N.-S., Mora-Rillo, M., Romero‐Gómez, M. P., Moreno-Ramos, F., Rico-Nieto, A., Carrascoso, G. R., Gómez-Gil, R., Arribas, J. R., Mingorance, J., & Paño‐Pardo, J. R. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12091 · Cited by 130
Satlin, M. J., Calfee, D. P., Chen, L., Fauntleroy, K. A., Wilson, S. J., Jenkins, S. G., Feldman, E. J., Roboz, G. J., Shore, T. B., HELFGOTT, D. C., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.723210 · Cited by 126
Weisenberg, S. A., Morgan, D. J., Espinal-Witter, R., & Larone, D. H. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.02.004 · Cited by 113
Clancy, C. J., Chen, L., Shields, R. K., Zhao, Y., Cheng, S., Chavda, K. D., Hao, B., Hong, J. H., Doi, Y., Kwak, E. J., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12424 · Cited by 112
Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint
Burkhardt, O., Rauch, K., Kaever, V., Hadem, J., Kielstein, J. T., & Welte, T. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.01.015 · Cited by 106
Berçot, B., Poirel, L., & Nordmann, P. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.08.016 · Cited by 103
Sbrana, F., Malacarne, P., Viaggi, B., Costanzo, S., Léonetti, P., Leonildi, A., Casini, B., Tascini, C., & Menichetti, F. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis969 · Cited by 100
McLaughlin, M. M., Advincula, M. R., Malczynski, M., Barajas, G., Qi, C., & Scheetz, M. H. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-31 · Cited by 94
Urban, C. M., Bradford, P. A., Tuckman, M., Segal‐Maurer, S., Wehbeh, W., Grenner, L., Colon‐Urban, R., Mariano, N., & Rahal, J. J. (2008) · Clinical Infectious Diseases · doi:10.1086/588048 · Cited by 92
Adaptive resistance to cationic compounds in Pseudomonas aeruginosa
Skiada, A., Markogiannakis, A., Plachouras, D., & Daikos, G. L. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.019 · Cited by 80
Self-citationDaikos, G. L., Markogiannakis, A., Souli, M., & TZOUVELEKIS, L. S. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.138 · Cited by 80
Self-citationKarageorgopoulos, D. E., Miriagou, V., TZOUVELEKIS, L. S., Spyridopoulou, K., & Daikos, G. L. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks270 · Cited by 60
Self-citationHirsch, E. B., Guo, B., Chang, K., Cao, H., Ledesma, K. R., Singh, M., & Tam, V. H. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis766 · Cited by 59
Wiskirchen, D. E., Nordmann, P., Crandon, J. L., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01947-13 · Cited by 51
β-Lactamase inhibitors: a review of the patent literature (2010 – 2013)
Buynak, J. D. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.831071 · Cited by 48
Combination therapy for Gram-negative bacteria: what is the evidence?
Kmeid, J., Youssef, M., Kanafani, Z. A., & Kanj, S. S. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.846215 · Cited by 45
Moreno, B. B., Fernández, I., García, V. P., Romero, I. S., Fernández, B. I., Ortega, M. Á. R., Carmona, S. A., Redondo, M. P., & Anuncibay, P. G. (2013) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2013.861608 · Cited by 42
Wiskirchen, D. E., Nordmann, P., Crandon, J. L., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01946-13 · Cited by 34
Tambyah, P. A., Hara, G. L., Daikos, G. L., Falagas, M. E., Mazzei, T., Mouton, J. W., Novelli, A., Chen, B., Wang, M., Ko, W., et al. (2013) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2013.04.002 · Cited by 7
Self-citation
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Torres, A., Niederman, M. S., Chastre, J., Ewig, S., Fernandez-Vandellos, P., Hanberger, H., Kollef, M., Li Bassi, G., Luna, C. M., Martin-Loeches, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00582-2017 · Cited by 1,387
Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance
Pitout, J. D. D., Nordmann, P., & Poirel, L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01019-15 · Cited by 852
Lee, C.-R., Lee, J. H., Park, K. S., Kim, Y. B., Jeong, B. C., & Lee, S. H. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00895 · Cited by 739
Carbapenem resistance: overview of the problem and future perspectives
Meletis, G. (2016) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936115621709 · Cited by 725
Metadata
- Authors
- Tzouvelekis, L. S., Markogiannakis, A., Piperaki, E., Souli, M., & Daikos, G. L.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 20
- Issue
- 9
- Pages
- 862-872
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2103549535
- Cited by
- 337
- References
- 63
- FWCI
- 15.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.